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ARTICLE
Physiologically Based Pharmacokinetic Models for Adults 
and Children Reveal a Role of Intracellular Tubulin Binding 
in Vincristine Disposition
Christine M. Lee1, Nicole R. Zane2, Gareth Veal3 and Dhiren R. Thakker1,*
Vincristine is a cytotoxic chemotherapeutic agent used as first-line therapy for pediatric acute lymphocytic leukemia. It is 
cleared by hepatic oxidative metabolism by CYP3A4 and CYP3A5 and via hepatic (biliary) efflux mediated by P-glycoprotein 
(P-gp) transporter. Bottom-up physiologically  based pharmacokinetic (PBPK) models were developed to predict vincris-
tine disposition in pediatric and adult populations. The models incorporated physicochemical properties, metabolism by 
CYP3A4/5, efflux by P-gp, and intracellular binding to β-tubulin. The adult and pediatric PBPK models predicted pharmacoki-
netics (PK) within twofold of the observed PK parameters (area under the curve, terminal half-life, volume of distribution, and 
clearance). Simulating a higher hypothetical (4.9-fold) pediatric expression of β-tubulin relative to adult improved predictions 
of vincristine PKs. To our knowledge, this is the first time that intracellular binding has been incorporated into a pediatric 
PBPK model. Utilizing this PBPK modeling approach, safe and effective doses of vincristine could be predicted.
The vinca alkaloid vincristine is a chemotherapeutic agent 
used as first-line therapy for pediatric acute lymphocytic 
leukemia (ALL) and acute myeloid leukemia. ALL is the most 
common pediatric cancer, accounting for 26% of cancer 
diagnosed in children up to 14 years of age. Younger chil-
dren are disproportionately affected by ALL, with the high-
est incidence in children 2–5 years old.1,2 Vincristine is also 
an important anticancer agent in other adult and pediat-
ric cancers, including Wilms tumor, Hodgkin disease, and 
non-Hodgkin lymphoma.3 Vincristine disrupts mitosis by 
binding to the β-tubulin subunits of intracellular microtu-
bule structures. This antimitotic effect is also responsible 
for its dose-limiting toxicity of peripheral neuropathy, often 
manifested by tingling, numbness, a burning sensation, and 
muscle weakness.4
Understanding the relationship between vincristine drug 
pharmacokinetics (PK) and risk of peripheral neuropathy is 
limited by sparse availability of clinical PK data.3 Increased 
risk of peripheral neuropathy has been reported in pediatric 
patients with reduced vincristine clearance, although sys-
temic exposure to vincristine has not been correlated with 
vincristine neurotoxicity.5,6 However, other studies indicate 
that clinical outcomes in children with ALL are related to the 
clearance and exposure of vincristine.7 Significant neurotox-
icity in pediatric patients has been observed when vincristine 
is coadministered with azole antifungals, which are potent 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Vincristine, a first-line treatment for pediatric can-
cer, is cleared by hepatic oxidative metabolism by 
CYP3A4 and CYP3A5 and via hepatic efflux mediated by 
P-glycoprotein (P-gp) transporter.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  The objective of the current study was to develop mech-
anistic physiologically based pharmacokinetic  (PBPK) 
models to predict the vincristine disposition of vincristine 
following i.v. administration to adults and children.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  The mechanistic PBPK models predict vincristine PK 
upon i.v. administration in adults and children. The models 
suggest that CYP3A5 and P-gp do not seem to play a 
significant role in the clearance of vincristine in adults or 
children. Interestingly, intracellular binding of vincristine to 
β-tubulin is a key parameter in the PBPK models for pre-
dicting the distribution phase of vincristine PK, and there 
may be age-related differences in the extent of intracel-
lular binding to β-tubulin.
HOW MIGHT THIS CHANGE DRUG DISCOVERY, 
DEVELOPMENT, AND/OR THERAPEUTICS?
✔  These PBPK models provide a useful tool to investi-
gate the relationship between vincristine exposure and 
clinical outcomes without invasive monitoring of plasma 
drug concentrations.
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CYP3A inhibitors (e.g., itraconazole and voriconazole), 
thereby increasing vincristine exposure.8 Nutritional status 
may also impact clinical outcomes and neurotoxicity risk by 
affecting clearance of the drug and hence exposure to it; 
in pediatric patients with Wilms tumor and malnutrition, de-
creased vincristine clearance (CL) and a twofold increase in 
exposure (area under the curve (AUC)) has been observed 
compared with pediatric patients without malnutrition.9
Pediatric PK data for vincristine are limited despite a 
long history of use in pediatric cancer. As a cytotoxic agent, 
vincristine is unlikely to be administered to healthy volun-
teers for prediction of vincristine PK or drug–drug interac-
tions. Therefore, understanding and predicting the potential 
age-related impact on vincristine disposition is essential for 
informing proper dosing and treating pediatric patients with 
cancer.
The objective of the current study was to develop physi-
ologically based pharmacokinetic (PBPK) models to predict 
the disposition of vincristine following i.v. administration to 
adults and children. Previously, we have developed bot-
tom-up PBPK models for pediatric disposition of voriconazole 
and sildenafil, which are both predominantly cleared via he-
patic oxidative metabolism.10,11 Like voriconazole and silde-
nafil, vincristine is metabolized by CYP3A4. Its clearance in 
infants and children, when normalized to body surface area 
or body weight, is higher than in adults, despite decreased 
CYP3A4 expression and activity in children.5,12,13 In contrast 
to voriconazole and sildenafil, vincristine is preferentially me-
tabolized by the genetically polymorphic enzyme CYP3A5, 
and it undergoes biliary excretion via P-glycoprotein (P-gp; 
also known as MDR1), a hepatic efflux transporter that is 
expressed at ~60% and 80% of adult levels in infants and 
children, respectively.14 Pediatric patients who are high ex-
pressers of CYP3A5 have higher metabolite plasma con-
centrations and lower incidence of peripheral neuropathy 
vs. low expressers.6 A similar approach could be applied to 
vincristine to predict its disposition in adults and children 
and thus assist in providing safe and effective dosing of this 
drug with a narrow therapeutic window.
METHODS
Materials
[3H]-Vincristine was purchased from American Radiolabeled 
Chemicals (St. Louis, MO). GW918 was a gift from 
GlaxoSmithKline (Research Triangle Park, NC). Madin-
Darby canine kidney strain II cells, expressing human P-gp 
after transfection with human MDR1 complementary DNA 
(MDCKII-MDR1), were obtained from the Netherlands 
Cancer Institute (Amsterdam, The Netherlands).
Cell culture
MDCKII-MDR1 cells were seeded at a density of 
100,000  cells/cm2 on 12-well Transwell plates (Corning, 
Corning, NY) and maintained in a CO2 incubator at 37°C. 
Cell monolayers were used for experiments 6  days after 
seeding.
Transport studies
To obtain estimates of apparent Michaelis-Menten constant 
(Km) and maximal flux (Jmax) for P-gp-mediated apical (AP) 
efflux of vincristine, in vitro transport studies were conducted 
with MDCKII-MDR1 cell monolayers overexpressing P-gp, as 
previously described.15 Monolayers were incubated in trans-
port buffer (pH 7.4) at 37°C. Dose solutions were added to 
the AP compartment for absorptive transport and basolateral 
(BL) compartment for secretory transport. To determine the 
transport of vincristine in the absence of P-gp activity (e.g., 
approximating conditions of permeability due to passive dif-
fusion),16 the P-gp inhibitor GW918 (1 μM) was included and 
transport determined. Samples were analyzed by liquid scin-
tillation spectrometry. Calculation of apparent Jmax and Km 
parameters for P-gp-mediated efflux of vincristine were per-
formed, as previously described, using nonlinear regression 
analyses (GraphPad Prism 7, La Jolla, CA).15
Pharmacokinetic data
Individual adult vincristine concentration-time data were 
 obtained by digitizing published PK profiles (GetData Graph 
Digitizer, version 2.26).17–19 Pediatric vincristine concen-
tration-time data were obtained from a PK study of 25 pa-
tients with localized Wilms tumors, with ages ranging from 
5 months to 9 years. Samples were analyzed at Newcastle 
University (UK) using a validated liquid chromatogra-
phy-mass spectrometry assay, as described previously.9 A 
subset of these concentration-time data has previously been 
published.9 Pediatric concentrations were dose-normal-
ized to account for the range of doses given (0.3–1.8 mg). 
Noncompartmental analysis was performed on the digitized 
adult concentration data and the pediatric concentration 
data using Phoenix 8.0 (Certara USA, Inc., Princeton, NJ).
PBPK model and simulation
A whole-body adult PBPK model was first developed using 
PK-Sim software (Open Systems Pharmacology Suite, ver-
sion 7.1) that incorporated vincristine physicochemical pa-
rameters (Table 1). Population-based PK simulations were 
performed for virtual adult (18–65 years old) and pediatric 
(0–9  years old) populations of 100 subjects each, com-
prising an equal proportion of male and female subjects. 
Physiologic parameters for the virtual adult population were 
generated based on the physiology of an average white 
American, as described in the 1997 National Health and 
Nutrition Examination Survey.
Age-relevant physiologic data from the International 
Commission on Radiological Protection were used to gen-
erate the virtual pediatric population.20 Human β-tubulin 
isotype class I (TUBB) was selected to represent overall β-tu-
bulin binding for this model, as it is both highly expressed 
and present in most human tissues.21 Gene expression 
levels of CYP3A4/5, P-gp, and TUBB were obtained from 
UNIGENE and E-GEOD databases using the PK-Sim built-in 
database query. CYP3A4 expression was adjusted for age 
using the built-in PK-Sim ontogeny function. The equation 
for CYP3A4 ontogeny in the liver used in PK-Sim is
where PMA is the postmenstrual age in weeks; A is the 
activity at PMA; A0.5 is the PMA at 50% activity compared 
with adults; and n is the Hill coefficient. As described in the 
A=PMAn∕(An
0.5
+PMA)
761
www.psp-journal.com
PBPK Models of Vincristine in Adults and Children
Lee et al.
PK-Sim Ontogeny Database version 7.3, an n of 3.331 and 
A0.5 of 73.019 is used by the PK-Sim software.
Rate constants for β-tubulin binding of vincristine have 
not been determined previously, as once bound to tubulin, 
the vincristine–tubulin dimers associate and form micro-
structures that interfere with light-scatter methods of de-
termining binding and dissociation constants.22 Therefore, 
published constants (koff, KD) for another vinca alkaloid of a 
similar chemical structure, vinblastine (Figure 1), were used 
and optimized by parameter estimation.
Parameter estimation was performed using the built-in 
PK-Sim tool on the kinetic parameters for P-gp transport 
(Km, Jmax) and specific binding to β-tubulin (koff, KD, and rel-
ative expression of TUBB). A multiple optimization approach 
was used with randomized start values.
Model evaluation
Model performance was evaluated by comparing simu-
lated plasma concentration-time profiles (population mean 
and 95% confidence interval (CI)) to observed concentra-
tion data. Models were accepted if simulated concentra-
tion-time profiles fit the overall shape of observed profiles, 
the majority of observed concentration data fell within the 
95% CI for simulated data, and the simulated PK parame-
ters were within two fold of the observed parameters.
Mean simulated adult PK parameters were compared 
with published experimental PK parameters derived from 
clinical studies of patients with cancer.17–19 Mean simu-
lated pediatric PK parameters were compared with the pe-
diatric PK results from 25 children (0–12 years; Newcastle 
University).23 Model robustness was further evaluated by 
comparing model simulations to additional published PK 
studies in which PK parameters (but not concentration data) 
were available.
Sensitivity analyses
Sensitivity analyses were performed using the PK-Sim 
tool to evaluate the effect of the metabolism (CYP3A4 
and CYP3A5 Km, maximum rate of metabolism (Vmax), and 
expression), P-gp efflux (Km, Jmax, and expression), and 
tubulin-binding (koff, KD, and TUBB expression) input pa-
rameters on performance of the adult PBPK model. These 
three parameters were selected for sensitivity analyses as 
potential significant contributors to vincristine distribution 
and clearance. Input values were evaluated with over a 
100% variation range (i.e., two fold) to determine the impact 
on the simulated PK parameters (AUC, CL, and volume of 
distribution (VD)).
RESULTS
PBPK model for vincristine disposition in adults after 
i.v. administration
The whole-body PBPK model structure is shown in 
Figure 1a. Tissue to plasma partition coefficients were de-
termined in PK-Sim using a method described by Schmitt.24
In vitro kinetic constants (Km and Vmax) for the formation of 
the vincristine metabolite M1 by recombinant CYP3A4 and 
CYP3A5 were used.25 Vincristine is metabolized by both 
CYP3A4 and CYP3A5, and the intrinsic clearance of vincris-
tine by CYP3A5 is ~12-fold higher than by CYP3A4, despite 
similar affinity of both enzymes for vincristine.25 Gene and 
protein expression of CYP3A4, but not CYP3A5, are age de-
pendent and follow a pattern of ontogeny.12 CYP3A5 is not 
highly expressed except in those with a specific genetic 
polymorphism.
Kinetic constants for P-gp efflux of vincristine in MDCK1-
MDR1 cells, determined experimentally in this study, were 
used for initial modeling. Although vincristine is well known 
as a substrate of P-gp, kinetic parameters of its efflux have 
Table 1 Vincristine parameters used for the adult and pediatric PBPK models
Parameter Value Source
Molecular weight, g/mol 824.958 PubChem
Solubility, mg/L 2.27
LogP 2.82 Hansch et al. (1995)40
pKa 5.00 and 7.4 Owellen et al. (1977)
41
fu 0.51 (α-1-acid glycoprotein) Mayer and St-Onge (1995)
36
Metabolism   rhCYP3A4 rhCYP3A5 Dennison et al. (2006)25
Vmax (pmol/min/pmol enzyme) 0.9 8.1
Km (μM) 19.8 14.3
P-gp transport Jmax (pmol/mL/min) Initial Optimized Experimental
416.1 416.1
Km (μM) 17.1 17.1
Specific binding to 
β-tubulin
  Initial Optimized Initial estimates for vinblas-
tine–tubulin binding by 
Lobert et al. (1996)22
koff (1/s) 8.30 × 10
−3 1.93 × 10−3
KD (μM) 0.05 0.05
Relative TUBB expression (μM) 1.00 1.00 (adult)
4.90 (pediatric)
UNIGENE and E-GEOD  
(PK-Sim database query)
fu, unbound fraction; Jmax, maximal rate of transport mediated by P-gp; KD, dissociation constant for binding of vincristine to β-tubulin; Km, Michaelis-Menten 
constant; koff, dissociation rate constant for binding of vincristine to β-tubulin; LogP, partition coefficient; PBPK, physiologically based pharmacokinetic; 
P-gp, P-glycoprotein; PK, pharmacokinetic; rhCYP3A4 and rhCYP3A5, recombinant human CYP3A4 and CYP3A5; TUBB, human β-tubulin isotype class I; 
Vmax, maximum rate of metabolism for CYP3A-mediated metabolism of vincristine.
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not previously been reported. Kinetic studies of P-gp efflux 
are often performed in vitro using inside-out membrane ves-
icle systems overexpressing MDR1; however, it is difficult to 
achieve adequate intravesicular concentrations of lipophilic 
compounds such as vincristine for evaluation.26,27 The per-
meability (Papp) of vincristine (10 μM) across MDCKII-MDR1 
monolayers is sevenfold greater in the BL to AP direction 
(157 nm/s) than in the AP to BL direction (22 nm/s), consis-
tent with AP efflux. Secretory transport of vincristine was 
significantly attenuated by GW918, an inhibitor of P-gp, de-
creasing the efflux ratio (Papp, BL to AP/Papp, AP to BL) from 7.1 
to 1.5, providing evidence that the AP efflux of vincristine is 
mediated by P-gp. An apparent Jmax of 46.6 pmol/min and 
Km of 17.1  μM was obtained for vincristine flux mediated 
by P-gp (R2 = 0.862). Based on the surface growth area for 
each Transwell (1.12 cm2) and average cell yield listed by the 
manufacturer (1.12 × 106 cells; Corning Guidelines for Use: 
Transwell Permeable Supports), the Jmax was estimated to 
be 416 pmol/min/million cells.
The adult PBPK model for vincristine that incorporates 
CYP3A4/5 metabolism, P-gp efflux, and specific binding to 
β-tubulin adequately described the observed concentration 
data (Table 1 and Figure 2). In vitro metabolism and trans-
port kinetics are scaled to organs by the following equation 
by PK-Sim:
in which Vmax,organ is the tissue-specific maximum ve-
locity, kcat is the catalytic rate constant (1/min), SF is the 
organ-specific scaling factor (μmol/L), erel is the relative ex-
pression of the enzyme or transporter protein, erel,s is the 
apparent catalytic rate constant, and Eo is the enzyme or 
transporter concentration in the organ (μmol/L).
For initial model building and optimization, an i.v. infusion 
(15 minutes) of 2 mg vincristine was simulated to match the 
Vmax,organ=kcat ⋅SF ⋅erel,organ=kcat,s ⋅erel,organ
Figure 1 Whole-body physiologically based pharmacokinetic (PBPK)  model for vincristine. (a) The model structure simulated by 
PK-Sim software package was adapted from Willmann et al. 42  The model includes simulation of the specific protein binding of 
vincristine to β-tubulin within the cellular compartment. Microtubule structures within the cell, comprising units of α-tubulin (represented 
by the triangles marked A) and β-tubulin subunits (represented by the triangles marked B), exchange subunits with an intracellular 
pool of unbound α-tubulin and β-tubulin, respectively. Vincristine enters the cell by passive diffusion and binds to the free intracellular 
β-tubulin.43 The chemical structures of vincristine and vinblastine are inset in (b), with differences between structures noted in red.
Figure 2 Simulation of vincristine concentration vs. time curve 
from 0  to  24  hours following a single i.v. dose of vincristine 
(2 mg) in a virtual adult population (N = 100). The solid red line 
represents the simulated mean, and the shaded area is the 95% 
confidence interval. The dotted lines represent the observed 
vincristine concentration vs. time profiles for 10 adults, extracted 
from publications by GetData.17,44 The inset panel shows the 
concentration vs. time curve for 0−4 hours only.
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dosing regimen of the observed clinical study that provided 
concentration data.19 A majority of these observed concen-
tration data were within the 95% CI of simulated vincristine 
plasma concentrations. To further evaluate the adult PBPK 
model, doses of 2  mg vincristine given by i.v. bolus and 
60-minute infusion were also used in order to evaluate sim-
ulated PK parameters as compared with those published 
in two other studies.18,28 Overall, the adult PBPK model pre-
dicted PK parameters (AUC, terminal half-life (t1/2), VD, and 
CL) well within a twofold margin of published parameters 
from all three PK studies (Table 2).
PBPK model for vincristine disposition in children 
after i.v. administration
The adult PBPK model for vincristine disposition was ini-
tially adapted to develop a pediatric model by incorpo-
rating age-related physiological differences, including the 
ontogeny of CYP3A4 expression. Although vincristine is 
also metabolized by CYP3A7, this enzyme is a fetal iso-
form that is not present after 6 months postnatal age.12,25 
Therefore, kinetic parameters for CYP3A4 and CYP3A5, but 
not CYP3A7, were included in the model. However, the sim-
ulation showed that vincristine distribution was not well de-
scribed by the model (Figure 3). Despite incorporating the 
tubulin-binding parameters (koff, KD) optimized in the adult 
PBPK model, the pediatric PBPK model overpredicted vin-
cristine concentrations relative to the  observed concen-
trations. The overprediction error was greatest with the 
concentrations in the first 4 hours after dose, suggesting 
that the extent of distribution of vincristine was being un-
derpredicted in the virtual pediatric population. Age-related 
differences in the expression of CYP3A4 and P-gp proteins 
do not explain the overprediction of vincristine concentra-
tions by the model, as they would be expected to impact 
the clearance of vincristine and not its distribution.14
Differences in specific binding to β-tubulin were con-
sidered potential factors affecting the distribution of vin-
cristine in children. Expression of TUBB was evaluated, 
because it is not known whether the expression of β-tubu-
lin isotypes is different in children compared with adults. 
To evaluate the effect of relative expression of TUBB on 
the distribution of vincristine in the virtual pediatric pop-
ulation, the pediatric expression of TUBB was varied up 
to 150-fold of the adult reference concentration and the 
PK parameters were simulated. Linear regression analysis 
demonstrated that in the simulated pediatric population, 
the VD of vincristine is significantly correlated with TUBB 
concentration (P  <  0.0001). Parameter estimation was 
also performed using adult relative expression of TUBB to 
optimize pediatric TUBB expression. Surprisingly, model 
optimization suggested that simulating a higher expres-
sion of TUBB in children (~4.9-fold of adult expression) 
improved predictions. Specifically, predictions of vincris-
tine concentrations in the distribution phase as well as 
prediction of pediatric VD and t1/2 improved significantly, 
although the AUC was underestimated to a greater extent 
(Figure 3b and Table 3). Following this adaptation, the 
pediatric model adequately described the observed pe-
diatric concentration data for vincristine. PK parameters Ta
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were also predicted within a twofold margin of published 
parameters (Table 3).
Sensitivity analyses
Sensitivity analyses demonstrated that simulated adult vin-
cristine area under the concentration-time curve from zero 
to infinity (AUC0−∞), t1/2, and CL are sensitive to CYP3A4 
Vmax and CYP3A4 expression (Table 4). A 100% increase 
in CYP3A4 relative expression decreased AUC and t1/2, and 
increased CL by >25%, indicating that CYP3A4 expression 
was an important parameter in the model for predicting vin-
cristine exposure and clearance. The PK parameters were 
not sensitive to CYP3A5 Vmax and relative expression in the 
model.
Changes in Km, Vmax, and relative expression of P-gp 
did not impact PK parameters; PK parameters changed 
by <10% when these input parameters were increased by 
100%.
The KD of tubulin binding to vincristine, as well as relative 
expression of TUBB, had a substantial impact on AUC0-∞, 
t1/2, and CL as well as vincristine VD. A 100% increase in 
KD caused an increase in AUC0-∞ by 20% and a decrease 
in t1/2, VD, and CL by 13%, 34%, and 21%, respectively. 
Increasing the relative expression of TUBB by 100% had the 
opposite effect, decreasing AUC0-∞ by 20% but increasing 
t1/2, VD, and CL by 30%, 50%, and 19%, respectively. In 
contrast, PK parameters were not sensitive to changes in 
the koff value.
DISCUSSION
Due to ethical considerations, development of pediatric 
drugs typically relies upon PK studies conducted in adults 
to arrive at safe and effective doses in children. Subsequent 
pediatric dose selection, PK predictions, and predictions 
of drug–drug interactions are thus extrapolated from adult 
data, adjusted by allometric scaling. However, allometric 
scaling does not address developmental changes in he-
patic function, renal function, organ sizes, or total body 
composition, nor does it account for the ontogeny of drug 
metabolizing enzymes or drug transporters. For example, 
the expression of CYP3A4 and the hepatic efflux trans-
porter P-gp demonstrates patterns of ontogeny that could 
impact the disposition of substrate drugs in infants and 
younger children.12,14 Bottom-up PBPK modeling provides 
a more rigorous approach to predict pediatric PK parame-
ters. In this approach, an adult PBPK model is first devel-
oped and validated using available clinical PK data, then 
adapted to a pediatric PBPK model by incorporating in vitro 
metabolism/transport data, generated using relevant pedi-
atric tissues, age-related changes in physiological parame-
ters, and the expression of drug-metabolizing enzymes and 
transporters. For drugs such as voriconazole and sildenafil 
that are cleared predominantly by oxidative metabolism, we 
previously demonstrated that mechanistic PBPK modeling 
approaches can be used to predict PK in children and pre-
mature neonates, respectively.10,11
In the present study, the objective was to apply this 
PBPK modeling approach to vincristine, which is cleared via 
P-gp-mediated hepatic efflux and CYP3A-mediated hepatic 
oxidative metabolism. Vincristine is used as the first-line 
therapy in common pediatric leukemias such as ALL and in 
pediatric solid tumor cancer treatment. Vincristine exhibits 
high interpatient variability, and there is limited availability of 
pediatric PK data. In some studies, but not others, correla-
tions have been shown between vincristine PK parameters 
Figure 3 Simulations of vincristine concentration vs. time in the virtual pediatric population (N = 100) with observed concentration data 
of 25 children, aged 0–12 years. The solid red lines represent the simulated mean, and shaded areas represent the 95% confidence 
interval (CI). Observed concentrations (circles connected by dotted lines) have been normalized to the dose (mg) received. (a) The 
pediatric population simulation with physiologically based pharmacokinetic model, using adult expression levels of human β-tubulin 
isotype class I  (TUBB). Relative TUBB expression in the virtual pediatric population was optimized by parameter estimation. As 
shown in (b), a higher expression of TUBB (4.9-fold increase relative to adult expression) improved predictions of pediatric vincristine 
concentrations, and more concentrations fall within the 95% CI compared with (a), particularly in the first 4 hours after dose. The inset 
panels in (a) and (b) show the concentration vs. time curves for 0−4 hours only.
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and clinical outcome as well as risk of the dose-limiting tox-
icity, peripheral neuropathy.5–7 Therefore, we believe that it 
is important to develop an adult mechanistic PBPK model of 
vincristine that can be validated using available clinical PK 
data and adapt it to a pediatric PBPK model that can guide 
dosing of the drug in pediatric patients with ALL and solid 
tumors.
Simulations with the initial adult model revealed that 
the distribution phase was not well predicted. Hence, we 
reasoned that because vincristine exerts its antimitotic ef-
fects by binding to intracellular β-tubulin subunits, this in-
tracellular binding may also impact the overall distribution 
of vincristine. By incorporating the binding of vincristine to 
β-tubulin, simulated plasma concentrations were adequately 
described in comparison to the observed concentration 
data, with the majority of observed data points falling within 
the 95% CI. The improved PBPK model was able to predict 
adult PK parameters of vincristine (AUC, t1/2, VD, and CL) 
within a twofold margin of the observed parameters from 
three published PK studies (Table 2). These results sug-
gested that binding to β-tubulin might have a key role in vin-
cristine distribution.
Sensitivity analyses were performed to evaluate the rel-
evance of the key processes that were incorporated in the 
PBPK model as determinants of the PK behavior of vincris-
tine. These analyses demonstrated that CYP3A4 Vmax and 
expression influenced simulated adult vincristine clearance 
and exposure (AUC), consistent with the reported predom-
inantly CYP3A4-mediated metabolism of vincristine.25 For 
example, a 100% increase in CYP3A4 relative expres-
sion decreased AUC and t1/2 and increased CL by >25% 
(Table 4). Although it has been reported that CYP3A5 plays 
a larger role than CYP3A4 in the metabolism of vincristine, 
changes in CYP3A5 Vmax and expression showed less im-
pact on vincristine PK parameters. This may be due to low 
or no CYP3A5 expression in the patient population provid-
ing the observed concentration data and PK parameters. 
Based on the location of the studies, the pediatric popula-
tion and the adult populations in the two published studies 
were presumed to be a majority of white and East Asian 
patients.19,28 The frequency of the nonfunctional variant, 
CYP3A5*3 allele (CYP3A5 nonexpresser), is 92–94% and 
71–75% for a white European and East Asian population, 
respectively.29 Contrary to expectations, sensitivity anal-
yses of P-gp Km and Jmax in the adult PBPK model indi-
cated that AUC, CL, or VD parameters did not change even 
upon a 100% increase in these kinetic parameters. Thus, 
it seems that biliary efflux via P-gp may not be the criti-
cal factor in defining vincristine hepatic clearance. Studies 
utilizing suspended cryopreserved human hepatocytes also 
indicate that the rate-limiting factor is not efflux via P-gp, 
which is consistent with the conclusion reached based on 
the sensitivity analyses but suggests a possible role of BL 
organic anion transporter proteins27 in rate-limiting uptake 
into hepatocytes.
The importance of intracellular binding of vincristine to 
tubulin is supported by the sensitivity of PK parameters to 
changes in the KD and TUBB values. Theoretical increases 
in the affinity for binding of vincristine to tubulin subunits 
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(by decreasing KD) or in the expression of TUBB would lead 
to increased intracellular binding. In both cases, sensitiv-
ity analyses suggest that an increase in intracellular binding 
would result in more extensive distribution (increase in VD) 
and decreased plasma levels  (AUC) of vincristine. In vitro, 
the intracellular accumulation of vincristine is strongly cor-
related with β-tubulin expression.30 In mice and dogs, tissue 
concentrations of vincristine and tissue-to-plasma partition 
coefficients were also highly correlated with β-tubulin binding 
capacity, suggesting that β-tubulin could also play an import-
ant role in tissue distribution and accumulation of vincristine 
in humans.31 Further corroboration of the importance of β-tu-
bulin binding to the distribution of vincristine is provided by 
mechanistic modeling of the taxane docetaxel, which binds 
to a different site of the β-tubulin subunit. Published mouse 
PBPK models of docetaxel incorporated the specific binding 
of docetaxel to β-tubulin (KD) and an estimated tubulin-bind-
ing capacity.32,33 When tubulin-binding capacity was adjusted 
for organ size, the mouse PBPK model was successfully 
adapted to predict docetaxel PK in adult humans.33 Although 
the ontogeny of β-tubulin expression is unknown, its expres-
sion and content vary by organ, as well as organ sizes, which 
are age dependent. Therefore, in addition to hepatic efflux by 
P-gp and metabolism by CYP3A enzymes, it is possible that 
the extent of intracellular binding to β-tubulin could differ in 
children vs. adults, due to differences in either β-tubulin ex-
pression or organ sizes.
The pediatric PBPK model was adapted from the adult 
model by incorporating age-related physiological dif-
ferences, including the ontogeny of CYP3A4 expression 
(CYP3A5 expression is not age dependent12). Although the 
sensitivity analyses indicated that P-gp might not play a 
significant role in determining PK parameters of vincris-
tine, the ontogeny of P-gp was also considered, as protein 
expression of P-gp is ~60% and 80% of adult levels in 
infants and children, respectively.14 We also considered 
the binding of vincristine to the plasma protein α-1-acid 
glycoprotein (AAG),34 as AAG levels increase with age.35 
Because vincristine is not extensively bound to AAG 
(fu 0.51) and AAG levels are lower in young children, this 
was not expected to explain the distribution of vincristine 
in children.36 Surprisingly, model optimization suggested 
that simulating a higher relative expression of TUBB in 
children (4.9-fold higher than adult expression) improved 
predictions of vincristine concentrations. To our knowl-
edge, the effect of age on tubulin expression has not 
previously been studied. We hypothesize that the greater 
extent of vincristine distribution observed in children com-
pared with adults was likely due to the pediatric PK sam-
ples being sourced from patients with large solid tumors 
(i.e., Wilms tumor). Gene expression of β-tubulin subunits 
in 15 pediatric patients with Wilms tumor was at least two 
fold greater as compared with noncancerous adult kidney 
tissue.37 Further in silico and in vitro studies are needed 
to understand the physiological basis for possible differ-
ences in tubulin binding that are associated with age.
There are two limitations of this study pertaining to the 
incorporation of β-tubulin into the PBPK models. First, pub-
lished values for vinblastine were used as the initial estimates 
for in vitro binding of vincristine to β-tubulin, because bind-
ing parameters for vincristine have not been reported in the 
literature. Vincristine and vinblastine are structurally similar 
vinca alkaloids (Figure 1), with similar thermodynamics and 
binding parameters to several β-tubulin isotypes.38 The vin-
blastine and vincristine equilibrium constants (K) for binding to 
tubulin subunits are similar (1.5 × 105 M−1 and 1.4 × 105 M−1, 
respectively).22 Published estimates of koff for vinblastine bind-
ing to β-tubulin range from 0.006 to 0.0083 1/s.22,39 In simu-
lations with the adult PBPK model of vincristine, decreases 
in koff by orders of magnitude were required to impact the 
simulation and decreased accuracy of the model predictions. 
Furthermore, a sensitivity analysis of koff indicates that increas-
ing this value by 100% does not impact simulated PK param-
eters of vincristine (Table 4). The value obtained for vincristine 
by parameter estimation, 0.00193 1/s, seems to be a reason-
able estimate based on the published vinblastine koff values. 
Second, expression of only one isotype of β-tubulin, TUBB, 
was used in the PBPK models due to its ubiquity in human 
Table 4 Sensitivity analyses of the effect of CYP3A4, CYP3A5, P-gp, and β-tubulin-binding parameters on vincristine PKs in adults
    AUC0−∞ t1/2 VD CL
CYP3A4 rhCYP Vmax −0.35 −0.36 −0.01 0.34
Relative expression −0.26 −0.26 −0.00139 0.25
CYP3A5 rhCYP Vmax −0.04 −0.04 0.00599 0.04
Relative expression −0.02 −0.02 −0.0002 0.02
P-gp Km −0.05 −0.00958 0.04 0.05
Vmax 0.05 0.0095 −0.04 −0.05
Relative expression −0.05 −0.00943 0.04 0.05
Binding to β-tubulin KD 0.20 −0.13 −0.34 −0.21
koff −0.00043 −0.00243 −0.002 0.000429
TUBB relative expression −0.20 0.30 0.50 0.19
AUC0−∞, area under the concentration-time curve from zero to infinity; CL, clearance; P-gp, P-glycoprotein transporter; PKs, pharmacokinetics; t1/2, terminal 
half-life; TUBB, human β-tubulin isotype class I; VD, volume of distribution; Vmax, maximal rate of metabolism.
Sensitivity analyses using the built-in PK-Sim tool were performed to evaluate effect of input parameters on performance of the adult physiologically based 
pharmacokinetic model. Input values were evaluated over a 100% variation range to determine impact on simulated adult PK parameters (e.g., a 100% in-
crease in CYP3A4 relative expression decreased AUC0−∞ and t1/2 by >25%. Overall, the analyses demonstrated that PK parameters are sensitive to changes 
in CYP3A4 relative expression, KD of β-tubulin binding to vincristine, and relative expression of TUBB.
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tissues, although there are eight human β-tubulin isotypes. 
Expression of these isotypes varies widely in the body; for ex-
ample, isotypes IIa and IVa are expressed almost exclusively 
in neural tissue.21 Further adaptation of the model to include 
additional isotypes of β-tubulin may be useful in understand-
ing vincristine distribution to specific organs and tissues.
In summary, the mechanistic PBPK models developed in 
this study predict vincristine PK in adults and children upon 
i.v. administration. Notably, the models yield interesting 
mechanistic information about the key determinants of the 
PK parameters of vincristine that could not have been ob-
tained through clinical studies. Specifically, the PBPK mod-
els suggest that CYP3A5 and P-gp, which were implicated 
in the clearance of vincristine from in vitro studies, do not 
play a significant role in the clearance of vincristine in ei-
ther adults or children. Further, we found that intracellular 
binding had to be invoked in building the model to describe 
and predict the distribution phase of vincristine PK. In retro-
spect, the rationale for the importance of intracellular bind-
ing in vincristine PK is clear, because binding to β-tubulin is 
the mechanistic basis for the anticancer activity of this drug. 
To our knowledge, this is the first example in which intracel-
lular binding has been incorporated into a pediatric PBPK 
model. Additionally, this study raises an interesting possibil-
ity that there may be age-related differences in the extent of 
intracellular binding to β-tubulin, leading to the correspond-
ing differences in vincristine PK in these two populations. 
We believe that PBPK modeling of vincristine disposition in 
children will improve the prediction of PK parameters in pe-
diatric patients, providing a useful tool to investigate the rela-
tionship between vincristine exposure and clinical outcomes 
without invasive monitoring of plasma drug concentrations.
Supporting Information. Supplementary information accompa-
nies this paper on the CPT: Pharmacometrics & Systems Pharmacology 
website (www.psp-journal.com).
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